Aktuelle Dermatologie 2025; 51(05): 155-166
DOI: 10.1055/a-2563-8859
State of the Art

Seltene Differenzialdiagnosen beim Ulcus cruris venosum

Norman-Philipp Hoff
,
Theresa M. Jansen
,
Martin Barsch
,
Sarah Janßen

Chronische Wunden stellen weltweit ein zunehmendes medizinisches und ökonomisches Problem dar. Die am häufigsten auftretenden chronischen Wunden manifestieren sich bei mehr als der Hälfte der Patient*innen als gefäßbedingte Ulzerationen. Die Ursachen für ein Ulcus cruris sind jedoch vielfältig. Insbesondere im dermatologischen Bereich werden häufig Patient*innen mit selteneren Ursachen für Unterschenkelulzerationen vorstellig. In diesem Artikel legen wir den Fokus auf seltene Differenzialdiagnosen des Ulcus cruris venosum (UCV).



Publication History

Article published online:
19 May 2025

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Manu C, Lacopi E, Bouillet B. et al. Delayed referral of patients with diabetic foot ulcers across Europe: patterns between primary care and specialised units. J Wound Care 2018; 27: 186-192
  • 2 Falanga V, Isseroff RR, Soulika AM. et al. Chronic wounds. Nat Rev Dis Primers 2022; 8: 50
  • 3 (Hrsg.) D. Lokaltherapie schwerheilender und/oder chronischer Wunden aufgrund von peripherer arterieller Verschlusskrankheit, Diabetes mellitus oder chronisch venöser Insuffizienz. . AWMF-Register-Nr: 091/001 2023; Version 2.1. Stand 11.09.2023.
  • 4 Dissemond J. ABCDE-Regel der Diagnostik chronischer Wunden. J Dtsch Dermatol Ges 2017; 15: 732-734
  • 5 Rabe E, Guex JJ, Puskas A. et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31: 105-115
  • 6 Korber A, Klode J, Al-Benna S. et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges 2011; 9: 116-121
  • 7 Maronese CA, Pimentel MA, Li MM. et al. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol 2022; 23: 615-634
  • 8 Flora A, Kozera E, Frew JW. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease. Exp Dermatol 2022; 31: 498-515
  • 9 Jockenhofer F, Wollina U, Salva KA. et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019; 180: 615-620
  • 10 Yamamoto T, Yamasaki K, Yamanaka K. et al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol 2023; 50: e253-e275
  • 11 Reid SD, Ladizinski B, Lee K. et al. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 2013; 69: 783-791
  • 12 Naumowicz M, Modzelewski S, Macko A. et al. A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation. Int J Mol Sci 2024; 25
  • 13 Peckruhn M, Tittelbach J, Elsner P. Update: Treatment of necrobiosis lipoidica. J Dtsch Dermatol Ges 2017; 15: 151-157
  • 14 Janßen S, Jansen TM. Ulcerated necrobiosis lipoidica successfully treated with tofacitinib. Int J Dermatol 2022; 61: 739-741
  • 15 Karppinen JJ, Kallio M, Lappalainen K. et al. Clinical characteristics of Martorell hypertensive ischaemic leg ulcer. J Wound Care 2023; 32: 797-804
  • 16 Kraus LF, Elsharkawi-Welt K, Peters T. et al. Diagnostic Challenge of Bilateral Martorell Hypertensive Ischaemic Leg Ulcers. Acta Derm Venereol 2021; 101: adv00457
  • 17 Pastor D, Toutous Trellu L. Martorell hypertensive ischemic ulcer: an atypical wound to know. Rev Med Suisse 2020; 16: 636-639
  • 18 Shanmugam VK, Angra D, Rahimi H. et al. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord 2017; 5: 280-292
  • 19 Shavit E, Alavi A, Sibbald RG. Vasculitis-What Do We Have to Know? A Review of Literature. Int J Low Extrem Wounds 2018; 17: 218-226
  • 20 Hoff NP, Homey B. Calciphylaxis. Pathogenesis and therapy. Hautarzt 2011; 62: 509-515
  • 21 Renner R, Dissemond J, Goerge T. et al. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. J Eur Acad Dermatol Venereol 2017; 31: 1884-1889
  • 22 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79
  • 23 Schiffmann ML, Dissemond J, Erfurt-Berge C. et al. German S1 guideline: diagnosis and treatment of livedovasculopathy. J Dtsch Dermatol Ges 2021; 19: 1668-1678
  • 24 Misciali C, Dika E, Fanti PA. et al. Frequency of malignant neoplasms in 257 chronic leg ulcers. Dermatol Surg 2013; 39: 849-854
  • 25 Valesky EM, Hach-Wunderle V, Protz K. et al. Diagnosis and treatment of venous leg ulcers: S2k Guideline of the German Society of Phlebology and Lymphology (DGPL) e.V. J Dtsch Dermatol Ges 2024; 22: 1039-1051
  • 26 Dissemond J. Medications. A rare cause for leg ulcers. Hautarzt 2011; 62: 516-523
  • 27 Akanay-Diesel S, Hoff NP, Kürle S. et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res 2011; 16: 491-494
  • 28 Best PJ, Daoud MS, Pittelkow MR. et al. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29-32
  • 29 Soya E, Makowski C, Blaise S. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?. Int Wound J 2019; 16: 897-902